沛嘉醫療-B(09996.HK)公佈年度業績:營收大增83.7%,經導管瓣膜治療業務取得大幅快速增長
格隆匯3月31日丨沛嘉醫療-B(09996.HK)公佈,截至2022年12月31日止年度,公司收入為人民幣2.51億元,同比增長83.7%。
由於出色的產品性能及專業的市場教育及推廣,經導管瓣膜治療業務取得大幅快速增長。全年,我們產品的入院數量和滲透率均不斷提升。
我們不斷努力達成2022年的業績指標,產品的入院進度良好。截至2022年12月31日,我們的產品共進入290家醫院,較截至2021年12月31日止年度,新增入院數量達到195家。
儘管整體市場受到新冠疫情的影響,我們的TaurusOne®及及TaurusElite®及產品銷售和植入進展穩健,屢創月度植入量新高。於報吿期內,經導管瓣膜治療業務收入較2021年同期增長155.9%,年內總植入量約為2021年總植入量的四倍。
得益於我們市場、銷售和醫學跨職能的專業團隊,經導管瓣膜治療業務上市後商業化發展快速。我們提供學術推廣、新技術合作、患者發現、術者培養、術前術中術後臨牀支持等全覆蓋的支持服務以及細緻完善的銷售服務。產品入院進度及已入院醫院,特別是核心醫院的植入量不斷攀升。商業化的快速推進,為公司的長期發展奠定了堅實的現金基礎。
隨着2022年神經介入業務四款缺血性產品的陸續上市,缺血性產品組合市場佈局良好;不斷豐富的缺血性產品線,加上具有先發優勢的出血產品線,神經介入業務收入構成將進一步多元化。
作為下一代經導管瓣膜治療方案的領跑者,我們通過創新技術搭建了一個廣泛且極具競爭力的產品管線,以滿足市場巨大的需求缺口。經導管瓣膜治療業務的主要在研產品已進入人體試驗階段;神經介入業務通過醫工結合,打造適合中國患者和術者的創新產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.